Literature DB >> 30149000

Melanoma-released exosomes directly activate the mitochondrial apoptotic pathway of CD4+ T cells through their microRNA cargo.

Ji Zhou1, Yi Yang1, WenWen Wang1, Yuan Zhang2, ZhengRong Chen3, ChuangLi Hao3, JinPing Zhang4.   

Abstract

Tumor-derived exosomes (TEX) play an important role in the escape of tumor cells from immune surveillance. However, the details of the mechanism are not fully understood. In this study, the apoptosis of CD4+ T cells increased during treatment with B16-derived exosomes in vitro and in vivo, resulting in accelerated growth of melanoma cells in mice. While the release of exosomes was blocked by disrupting the expression of Rab27a, tumor growth was clearly inhibited, and the percentage of T cells in the tumor environment increased. At the same time, Western blot showed that TEX could increase the activation of caspase-3, caspase-7 and caspase-9 but not caspase-8, down-regulating the anti-apoptotic proteins, including BCL-2, MCL-1 and BCL-xL in CD4+ T cells, and indicating that the TEX activates the mitochondrial apoptotic pathway of CD4+ T cells. These reductions were probably associated with the release of microRNAs, such as miR-690, from TEX to T cells. Our present study reveals for the first time that melanoma-released exosomes may directly activate the mitochondrial apoptotic pathway of CD4+ T cells through their microRNA cargo.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Exosomes; T cells; Tumor microenvironment; microRNAs

Mesh:

Substances:

Year:  2018        PMID: 30149000     DOI: 10.1016/j.yexcr.2018.08.030

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  13 in total

Review 1.  Role of exosomes in tumour and transplant immune regulation.

Authors:  Diego A Lema; William J Burlingham
Journal:  Scand J Immunol       Date:  2019-07-31       Impact factor: 3.487

Review 2.  Signaling of Tumor-Derived sEV Impacts Melanoma Progression.

Authors:  Aneta Zebrowska; Piotr Widlak; Theresa Whiteside; Monika Pietrowska
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

Review 3.  Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models.

Authors:  Marvin Droste; Basant K Thakur; Brian P Eliceiri
Journal:  Front Immunol       Date:  2020-12-16       Impact factor: 7.561

Review 4.  Exosomes in Immune Regulation.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Noncoding RNA       Date:  2021-01-08

Review 5.  The Roles of Extracellular Vesicles in Malignant Melanoma.

Authors:  Ying-Chen Cheng; Yu-An Chang; Yi-Jen Chen; Hsu-Min Sung; Ivan Bogeski; Hong-Lin Su; Ya-Ling Hsu; Hui-Min David Wang
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

Review 6.  Exosomes as mediators of immune regulation and immunotherapy in cancer.

Authors:  Fernanda G Kugeratski; Raghu Kalluri
Journal:  FEBS J       Date:  2020-10-03       Impact factor: 5.622

Review 7.  The role of cancer-derived microRNAs in cancer immune escape.

Authors:  Ming Yi; Linping Xu; Ying Jiao; Suxia Luo; Anping Li; Kongming Wu
Journal:  J Hematol Oncol       Date:  2020-03-28       Impact factor: 17.388

Review 8.  The Influence of Tumor Microenvironment on Immune Escape of Melanoma.

Authors:  Aleksandra Simiczyjew; Ewelina Dratkiewicz; Justyna Mazurkiewicz; Marcin Ziętek; Rafał Matkowski; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

Review 9.  New Insights into the Role of Sphingolipid Metabolism in Melanoma.

Authors:  Lorry Carrié; Mathieu Virazels; Carine Dufau; Anne Montfort; Thierry Levade; Bruno Ségui; Nathalie Andrieu-Abadie
Journal:  Cells       Date:  2020-08-26       Impact factor: 6.600

Review 10.  Role of microenvironmental acidity and tumor exosomes in cancer immunomodulation.

Authors:  Zaira Boussadia; Cristiana Zanetti; Isabella Parolini
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.